Metformin Reduces Cancer Risk in Diabetic Patients
Author Information
Author(s): Lee Meei-Shyuan, Hsu Chih-Cheng, Wahlqvist Mark L, Tsai Hsin-Ni, Chang Yu-Hung, Huang Yi-Chen
Primary Institution: National Defense Medical Center, Taipei, ROC
Hypothesis
Does metformin reduce the incidence of various cancers in patients with type 2 diabetes?
Conclusion
Metformin can reduce the incidences of several gastroenterological cancers in treated diabetes.
Supporting Evidence
- Cancer incidence density increased at least 2-fold for total, colorectal, and liver cancers in diabetes patients without medication.
- On metformin, cancer incidences decreased to near non-diabetic levels.
- Metformin dosage for significant cancer incidence reduction was ≤500 mg/day.
Takeaway
If you have diabetes and take metformin, you might get less cancer than if you don't take it.
Methodology
A cohort of 480,984 diabetes-cancer-free participants was formed and categorized by diabetes and metformin usage status, with cancer events tracked until the end of 2007.
Potential Biases
Potential selection bias due to the prescription of metformin affecting the observed cancer risk.
Limitations
The study did not have systematic clinical measurements available for BMI or obesity, which could confound results.
Participant Demographics
Participants were primarily Taiwanese, with a majority over 50 years old and a mix of genders.
Statistical Information
P-Value
0.36 for CRC
Confidence Interval
0.08-0.19 for total cancer
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website